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relationship between the EQD2 for both treatment locations 
(CRT, SDRT) and the occurrence of a first CVA was assessed. 
Results: After a median time of 24.9 years from the primary 
diagnosis and at a median attained age of 31.2 years, 28 
survivors had a first CVA. Of them, 18 (64.3%) had ischemic 
events (Grade 3-4), and 10 (35.7%) had hemorrhagic events 
(Grade 2-5). One survivor was not treated with CRT nor with 
SDRT. Subsequently, two survivors had a second, and one a 
third CVA. The 35-year cumulative hazard in survivors treated 
with CRT only was 14.2% (95%CI, 3.5-24.9%), in survivors 
treated with SDRT only 6.8% (95%CI, 0-13.7%), and in 
survivors who received both CRT and SDRT 24.3% (95%CI, 6.7-
41.8%) (Figure). The Cox analyses showed that both 
treatment locations significantly increased the risk of CVA in 
a dose-dependent manner (HRCRT 1.02 Gy-1; 95%CI, 1.01-1.03, 
and HRSDRT 1.04 Gy-1; 95%CI, 1.02-1.05). 
 
 
Figure. Cumulative hazards and 95%CIs for the first CVA ≥5 
years after the primary cancer diagnosis in survivors treated 
with CRT only, SDRT only, both CRT and SDRT, and in 
survivors who had no CRT and no SDRT. 
Note: The SDRT only group consisted of 95 survivors; SDRT 
treatment could not be confirmed for 3 survivors, leaving 92 
survivors for analysis. 
Conclusions: Our results demonstrate that childhood cancer 
survivors treated with CRT and/or SDRT have an increased 
risk of CVAs as compared with survivors who had no CRT and 
no SDRT. Thirty-five years after treatment, almost 1 in 4 
childhood cancer survivors treated with both CRT and SDRT 
experience a symptomatic CVA. In addition, these radiation-
associated CVAs occur at a very young age. Therefore, 
continuing follow-up with a focus on tailored preventive 
strategies to reduce the risk of CVAs in this young population 
deserves special attention. 
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Purpose/Objective: Paediatric metastatic medulloblastoma 
requires intensive treatment for the best results. Since 2007 
the majority of UK centres used the Milan strategy (High dose 
Chemotherapy and twice daily Radiotherapy) to treat these 
patients. There were some reported cases of profound 
neurotoxicity and a review of plans and treatment method 
was done in order to check whether radiotherapy had 
contributed to the toxicity. 
Materials and Methods: Patients with Grade 3-4 
neurotoxicity, treated between 2008 and 2014, were 
identified and the toxicities classified into global and 
myelitis. Plan data (CT planning scans, Plans and Dosegrids) 
for the CranioSpinal (CNS) phase 1 and the Posterior Fossa 
Boost (PFB) phase 2 , was collected and imported into Eclipse 
(Varian). The dosimetry was reviewed for individual and 
summed phases. Where possible MR images showing myelitis 
were blended with the dose distribution on the CT scan. A 
questionnaire was circulated around all Centres to establish 
the RT technique and immobilisation used. 
Results: 10 cases (8 male, all under 12 years), from 6 Centres 
were reviewed. All the children had a poor response to 
induction chemotherapy and received thiotepa as part of 
their high dose chemotherapy regime. The CNS dose was 
39Gy in 30 Fr for 9 cases and 31.2 Gy in 1 Fr for 1. All 
received a PFB to a dose of 59.7 – 60 Gy. All Centres used a 
conformal Linac based technique with opposed Head fields 
matched to posterior Spine fields, and a shifting gap. 5 out of 
6 centres used a supine technique. 1 Centre used VMAT for 
the PFB, others a 3DCRT plan. 1 Centre checked plans using 
summed doses, others checked each phase separately. The 
myelitis occurred in the PFB volume and it was noted that for 
these patients the C1 summed dose was >62 Gy, although less 
than 63Gy (105%), see Fig 1.  
 
 
Conclusions: There was no evidence of radiation techniques 
contributing to neurotoxicity. However when the Milan 
protocol was adapted for the UK, there was no involvement 
of physics and certain details of the treatment were 
different, in particular that in Milan the PFB PTV would not 
include the spinal cord. This review also highlighted the 
importance of planning and summing both phases in order to 
assess the combined dose. It is recommended that special 
attention is paid to the cervical spinal cord dose with a strict 
dose constraint of 61Gy. Lessons learnt from this review 
highlight the importance of sharing experience both 
nationally and internationally especially for rare tumours. 
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Stereotactic Body Radiotherapy (SBRT) is today the accepted 
standard of care for early stage non-small cell lung cancer if 
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patients are inoperable due due medical co-morbidities: local 
tumor control is achieved in >90% of the patients resulting in 
improved overall survival (OS). Based on the promising 
experiences in primary lung cancer and other cancer sites, 
SBRT is currently explored in the setting of oligo-metastatic 
disease. In this rather rare clinical setting, patients with a 
limited number of metastases (maximum 3-5) in a limited 
number of organs (1-2) are treated locally aiming at 
prolongation of disease-free interval, treatment-free interval 
and eventually overall survival. Despite the value of any local 
treatment in the metastatic setting has not been proven in 
randomized clinical trials, surgery is the guideline-
recommended treatment of choice in many cancers e.g. 
colorectal cancer or renal cell cancer. This presentation will 
outline the rational of using SBRT in the oligo-metastatic 
setting, give a summary of current evidence and compare 
SBRT with other local treatment options especially surgical 
resection. 
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SABR for oligometastatic disease is a favourite pastime for 
radiation oncologists looking for application of high precision 
hypofractionated conformal radiotherapy. This is often 
fuelled by interests in technology of treatment delivery not 
infrequently vested in equipment suited for this technique. 
Yet SABR is just one of a spectrum of local therapies for small 
lesions (which include surgery and thermal ablation) and 
evidence for benefit of real value to the patient is weak. 
There is reasonable consensus that SABR can achieve 
prolonged control of individual lesions with reasonable safety 
providing the lesions are small and the dose is delivered 
within radiation tolerance of the structure they are lodged 
in. However, evidence of real benefit for the patient in terms 
of prolonging survival and improving or maintaining quality of 
life is hard to come by. The problems include the lack of 
validated definition of oligometastatic disease, inevitable 
patient selection and the consequent reporting bias and the 
lack of randomised studies. In this setting, SABR for 
oligometastatic disease cannot be considered the standard of 
care. 
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Few evidences are available to justify the integration of 
stereotactic ablative radiotherapy (SABR) with current 
systemic approaches in metastatic disease, especially in the 
first-line setting. The use of SABR is supported by low-level 
evidence due to retrospective nature of published 
experiences, heterogeneous group of patients treated across 
studies, different techniques adopted, different dose and 
fractionation chosen, different endpoints evaluated, short 
follow-up, little or no data regarding late  and early late 
toxicity. 
Although in most cases very good rate of local control are 
reported with good toxicity profile, no large studies 
demonstrated the significant impact of SABR for 
oligometastases on disease-free and overall survival of 
patients. 
Prospective experience are strongly required to evaluate the 
potential impact of SABR in the context of standard systemic 
therapies in a homogeneous disease population, on improving 
progression-free survival, time to progression, and hopefully 
overall survival. An overview on the attractive challenge 
between technical innovation and clinical benefit. 
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Regional radiotherapy (RT) is generally offered to patients 
operated for node-positive early breast cancer (BC), in 
particular if >3 nodes are involved. Despite results from 
randomised trials indicating beneficial effect from regional 
RT in patients with 1-3 positive nodes (pN1) many of these 
patients are not offered regional RT routinely (Overgaard et 
al, NEJM 1997, Lancet 1999, R&O 2007, Ragaz et al, NEJM 
1997). The reluctance may be due to a relatively high 
incidence of loco-regional recurrences (LRR) and poor overall 
survival (OS) in the trials compared to retrospective studies 
in the same type of patients treated without regional RT in 
the same period. Recently the randomised MA.20 trial, which 
included 1832 patients (85% of the patients had pN1 disease) 
treated with breast conservation 2000 to 2007, confirmed the 
beneficial effect of regional RT (Whelan et al, ASCO 2011, 
abstract). Even node-negative patients operated for a medial 
or centrally located BC may have a survival gain from 
irradiating the internal mammary nodes (IMN) and medial 
supraclavicular (MS) nodes as demonstrated in the EORTC 
22922/10925 Trial (Poortmans et al, ECCO 2013, abstract). It 
is thus likely that the use of regional RT will increase with 
the publication of these 2 trials. 
A new group of patients is now being proposed as candidate 
for regional RT based on the AMAROS study (Donker et al, 
Lancet Oncol 2014). In that trial patients diagnosed with T1-2 
and sentinel node positive BC were randomised to axillary 
lymph node dissection (ALND) versus axillary RT. The 1425 
patients had an excellent and comparable loco-regional and 
distant control, but significantly more lymph oedema was 
seen in the ALND group favouring regional RT.  
There are several concerns when planning regional RT, and 
one is the decision on optimal target delineation. An ESTRO 
consensus for this is now published. Another concern is the 
decision about which lymph node levels are the relevant 
targets to be irradiated. The EORTC 22922/10925 Trial 
adressed this when randomising 4004 stage I-III patients to ± 
RT to the IMN and MS nodes, and showed a gain in 10 year 
DFS and MFS. The DBCG IMN study based on >3000 patients 
also showed an OS gain in node positive patients if the IMN 
were included in the RT fields (Thorsen et al, EBCC 2014, 
abstract). A third concern is dose and fractionation, because 
most studies have used 50 Gy/25 fr, but since the publication 
of a Canadian trial and the START Trial B more centres are 
now using hypofractionation based on 40-42,5 / 15-16 fr for 
regional RT despite only limited data support this. Of 
